A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Afatinib (Primary) ; Methotrexate
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms LUX-Head and Neck-3
- Sponsors Boehringer Ingelheim
- 23 Sep 2024 Planned End Date changed from 31 Oct 2024 to 30 Apr 2025.
- 15 Jul 2024 Planned End Date changed from 31 Aug 2024 to 31 Oct 2024.
- 02 Apr 2024 Planned End Date changed from 30 May 2024 to 31 Aug 2024.